Endpoint selection in HER2-positive early breast cancer

The Lancet Oncology

Fecha de publicación: 29 january 2019

DOI: https://doi.org/10.1016/S1470-2045(18)30779-4

Autores: Eitan Amir

Background: Compared with definitive endpoints such as overall survival, the use of intermediate endpoints such as disease-free survival improves the efficiency of trial design, resulting in studies requiring smaller sample sizes and shorter follow-up. In oncology, the validation of intermediate endpoints as adequate surrogates of definitive outcomes is challenging.

Seguir leyendo